Hormone replacement therapy and increased plasma concentration of C-reactive protein.
about
C-reactive protein: a critical updateRole of C-reactive protein in cardiovascular diseaseCritical appraisal of C-reactive protein throughout the spectrum of cardiovascular diseaseIncome, education, and inflammation: differential associations in a national probability sample (The MIDUS study)Association between inflammatory biomarkers and bone mineral density in a community-based cohort of men and womenInfluence of low birth weight on C-reactive protein in asymptomatic younger adults: the bogalusa heart study.The role of C-reactive protein in cardiovascular disease risk.Hormone replacement therapy and cardiovascular risk.Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomyHRT to prevent cardiovascular disease. What studies show, how to advise patients.Direct effects of estrogen on the vessel wall.Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomes.Invited review: Pharmacogenetics of estrogen replacement therapy.Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention programEffects of transdermal estrogen replacement therapy on cardiovascular risk factors.Vascular inflammation as a therapeutic target for prevention of cardiovascular disease.Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs.Association of circulating C-reactive protein and interleukin-6 with longevity into the 80s and 90s: The Rancho Bernardo Study.Postmenopausal hormone replacement therapy and atherosclerosis.High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment.Molecular mechanisms of diabetic cardiovascular disease.Role of inflammation in cardiovascular disease: how to use C-reactive protein in clinical practice.Divergent effects of a combined hormonal oral contraceptive on insulin sensitivity in lean versus obese womenC-reactive protein and risk of colorectal adenoma according to celecoxib treatment.High Sensitivity C - Reactive Protein is Associated with Diastolic Dysfunction in Young African Americans without Clinically Evident Cardiac DiseaseC-reactive protein and cardiovascular disease: new insights from an old molecule.What is the influence of hormone therapy on homocysteine and crp levels in postmenopausal women?Hormone replacement therapy and cardioprotection: the end of the tale?Factors associated with inflammation markers, a cross-sectional analysis.Insulin resistance with hormone replacement therapy: associations with markers of inflammation and adiposityTrends in health of older adults in the United States: past, present, future.C-reactive protein and end-stage renal disease.The effect of weight loss on a stable biomarker of inflammation, C-reactive protein.Changes in postmenopausal hormone therapy use since 1988.Is there a link between oestrogen therapy and gallbladder disease?Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article.C-reactive protein, inflammatory conditions, and cardiovascular disease riskUrinary lignans and inflammatory markers in the US National Health and Nutrition Examination Survey (NHANES) 1999-2004 and 2005-2008.Influence of smoking and body weight on adipokines in middle aged women.Factors Associated with Multiple Biomarkers of Systemic Inflammation.
P2860
Q24672855-8E32BF1A-713A-455B-A80C-43388155ACA8Q28166927-A72224BD-C8D6-4917-9B07-4D313960AC80Q28219483-3E51BECF-42A3-409D-9919-06A0AEED5DA0Q33793994-A744C010-1A8F-4D99-A62D-FCBD8406C710Q33800888-FC665D19-7766-47A2-A81A-21CB71D53468Q33850394-5F372128-C633-4605-B25C-2C5DBF40100AQ34011157-B4B26275-C966-4638-92F7-F40E1D0E4E3DQ34011174-86296657-42AA-42D4-B63E-EFC47189F6EDQ34037822-03066C36-5031-461C-9D60-D8111658E7A0Q34044754-0E8176B6-732E-40D1-9BB2-2480388398B3Q34165126-C0995574-0157-4841-8003-5E7753796904Q34283107-D98ED509-95F2-46AA-90C2-0CD6E006E8D8Q34444907-3BAC1463-D182-4FF1-B385-68084F2089FEQ34457386-3F0E82BD-8D52-41A1-8E55-A8F975CB531EQ34482114-83C94895-27C8-4DAB-9E1E-E9517974D260Q34514026-1DC630FE-ABE6-4093-9C5E-6C898C961C77Q34629246-EE28B65D-B782-4FA1-BA26-8422FA46BB7DQ34630713-2AE843BF-FDCC-4AEE-ACE3-A6159243D71CQ34774237-37ECC833-53E4-42AB-A305-E22C585174CFQ34973446-5D9E2BBE-6A6B-410E-A348-1952B0C2BBAAQ34989681-30CE2F7E-7F75-4CE1-B61A-1743A050E92DQ34989707-81AF2652-13BA-471B-8DE3-C14057206C27Q35127091-4CC893EC-3061-4EA8-AE04-189CD29A5B24Q35152176-10AF0059-D9A3-449D-9F7F-6F9B5CB71C3EQ35207988-FC7E89B9-AD01-4CDD-A4AB-ABD373BB3A16Q35562701-1A115C67-2E28-472A-A7A9-BA1F0DABB363Q35583454-C1CA7535-6095-424C-AA1B-53FD43A41BEAQ35596294-8C70C992-109D-4A8F-8F89-F56F60E031C0Q35633792-2C6AE00C-2FD5-4001-9680-DF503FCCD372Q35728222-6B929D70-5C70-402A-A4DF-DE5EC2C2B0A6Q35928889-DDF1AF5C-1B1F-4F1D-8BEB-DED3A78170FCQ36014794-8CE7AC93-0C52-4167-B653-EC0839BBCEC1Q36053976-EDEB789D-E2B3-4465-B6A4-AC70C515B01DQ36334352-9F5E495F-3833-48D8-A955-744F863649EAQ36349751-5E559255-2679-4440-BBBD-182E1E8D4232Q36359547-43FDE6E1-B588-45C9-B71B-4187E1DF4662Q36408376-AC49F052-D50C-4D0D-AA7C-C384FC2780C4Q36416423-9E00724E-C66E-48BB-8209-AEA8411902FFQ36464223-B60E3C4E-2452-4E0B-BC67-902F82F302E5Q36655802-147DFFA0-EC33-41DF-96B6-CC40387431C9
P2860
Hormone replacement therapy and increased plasma concentration of C-reactive protein.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Hormone replacement therapy and increased plasma concentration of C-reactive protein.
@en
type
label
Hormone replacement therapy and increased plasma concentration of C-reactive protein.
@en
prefLabel
Hormone replacement therapy and increased plasma concentration of C-reactive protein.
@en
P2093
P356
P1433
P1476
Hormone replacement therapy and increased plasma concentration of C-reactive protein.
@en
P2093
P304
P356
10.1161/01.CIR.100.7.713
P407
P577
1999-08-01T00:00:00Z